Lombard Odier Asset Management (Switzerland) Sa Incyte Corp Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $3.84 Million - $4.7 Million	-54,679 Reduced 22.12%	192,505 $13.9 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $1.27 Million - $1.59 Million	-18,889 Reduced 7.1%	247,184 $19.9 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $512,762 - $641,999	-7,748 Reduced 2.83%	266,073 $17.7 Million
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $3.88 Million - $4.88 Million	-58,677 Reduced 17.65%	273,821 $20.8 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $22 Million - $26.5 Million	332,498 New	332,498 $26.4 Million

Others Institutions Holding INCY

# of Institutions

644

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account